EUVIMEDEUVIMED entdecken
Crossref

Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy

Rikuya Torigoe, Taro Oshikiri, Hironobu Goto, Yasuhumi Koterazawa, Ryuichiro Sawada, Taro Ikeda, Hitoshi Harada, Naoki Urakawa, Hiroshi Hasegawa, Shingo Kanaji, Kimihiro Yamashita, Takeru Matsuda und 1 weitere

Anticancer Research · 2024

DOI: 10.21873/anticanres.17374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Rikuya Torigoe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan. Hauptthemen laut MEDLINE: Esophagectomy, Serpins, Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Squamous cell carcinoma antigen (SCC) is widely used as a tumor marker for esophageal cancer. In this study, we investigated the relationship between SCC and long-term outcomes in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy (NAC) followed by minimally invasive esophagectomy (MIE). PATIENTS AND METHODS: Between 2010 and 2018, 124 patients with ESCC who underwent MIE after NAC (cisplatin plus 5-fluorouracil) were included. Patients were divided into low and high groups based on their pre-NAC SCC level, according to the cut-off value determined using a receiver operating characteristic curve. These two patient groups were further divided into subgroups by receiver operating characteristics according to whether SCC was low or high after NAC. RESULTS: For overall survival (OS), the cut-off value for SCC pre-NAC was 0.9 ng/ml. Ninety-six patients were in the high SCC group (≥0.9 ng/ml) and 28 patients were in the low SCC group (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EsophagectomySerpinsEsophageal Squamous Cell CarcinomaNeoadjuvant TherapyEsophageal NeoplasmsAntigens, NeoplasmHumansMaleFemaleMiddle AgedAgedPrognosisFluorouracilAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorAdultCisplatinChemotherapy, AdjuvantMinimally Invasive Surgical ProceduresRetrospective Studies

Stichwörter der Autor:innen

Esophageal squamous cell carcinomaminimally invasive esophagectomyneoadjuvant chemotherapysquamous cell carcinoma antigentumor marker

Substanzen

squamous cell carcinoma-related antigenSerpinsAntigens, NeoplasmFluorouracilBiomarkers, TumorCisplatin

Autor:innen und Institutionen

  • Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan.
  • Division of Gastrointestinal Surgery and Surgical Oncology, Graduate School of Medicine, Toon, Japan oshikiri.taro.th@ehime-u.ac.jp.

Zitieren

APA

Torigoe, R., Oshikiri, T., Goto, H., Koterazawa, Y., Sawada, R., Ikeda, T., Harada, H., Urakawa, N., Hasegawa, H., Kanaji, S., Yamashita, K., Matsuda, T., & Kakeji, Y. (2024). Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy. Anticancer Research. https://doi.org/10.21873/anticanres.17374

Vancouver

Torigoe R, Oshikiri T, Goto H, Koterazawa Y, Sawada R, Ikeda T, et al. Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy. Anticancer Research. 2024. doi:10.21873/anticanres.17374

BibTeX
@article{Torigoe2024,
  author = {Torigoe, Rikuya and Oshikiri, Taro and Goto, Hironobu and Koterazawa, Yasuhumi and Sawada, Ryuichiro and Ikeda, Taro and Harada, Hitoshi and Urakawa, Naoki and Hasegawa, Hiroshi and Kanaji, Shingo and Yamashita, Kimihiro and Matsuda, Takeru and Kakeji, Yoshihiro},
  title = {Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17374}
}
Kostenlos starten →